Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02891226
Registration number
NCT02891226
Ethics application status
Date submitted
1/09/2016
Date registered
7/09/2016
Titles & IDs
Public title
A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease
Query!
Scientific title
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
Query!
Secondary ID [1]
0
0
I6T-MC-AMAG
Query!
Secondary ID [2]
0
0
16492
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SERENITY
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Crohn's Disease
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Inflammatory bowel disease
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Crohn's disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Experimental: Mirikizumab - Period 1 (Weeks 0 -12): 200 Milligram (mg), 600 mg, and 1000 mg mirikizumab administered intravenously (IV) every 4 Weeks (Q4W).
Period 2 (Weeks 12 - 52): 200 mg, 600 mg, and 1000 mg mirikizumab administered IV Q4W; 300 mg mirikizumab administered subcutaneously (SC) Q4W; 1000 mg mirikizumab administered IV Q4W for non-improvers in period 1; and 1000 mg mirikizumab administered IV Q4W for participants on placebo during period 1.
Period 3 (Weeks 52 - 208): 300 mg mirikizumab administered SC Q4W.
Placebo comparator: Placebo - Period 1 (Weeks 0 -12): Participants received placebo administered intravenously (IV) Q4W.
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Achieving Endoscopic Response at Week 12
Query!
Assessment method [1]
0
0
Endoscopic response defined as = 50% reduction from baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 12. The SES-CD evaluates 4 endoscopic variables: presence and size of ulcers, proportion of surface covered by ulcers, proportion of surface affected by disease, and presence and severity of stenosis. The total SES-CD calculated as sum of 4 variables for 5 bowel segments: (ileum;right,transverse,and left colon;and rectum): presence and size of ulcers (none = score 0; diameter 0.1-0.5 cm = score 1; 0.5-2 cm = score 2; \>2 cm = score 3); extent of ulcerated surface (none = 0; \<10% = 1;10-30% = 2;\>30% = 3);extent of affected surface (none = 0; \<50% = 1;50-75% = 2;\>75% =3); and presence and type of narrowings (none=0; single, can be passed=1; multiple,can be passed=2; cannot be passed=3). Total SES-CD scores range from 0 to 56, with higher scores indicating more severe disease.
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [1]
0
0
Percentage of Participants Achieving Endoscopic Remission at Week 12
Query!
Assessment method [1]
0
0
Endoscopic remission defined as SES-CD of \<4 ileal-colonic or \<2 for isolated ileal disease, and no subscore \>1 at week 12. The SES-CD evaluates 4 endoscopic variables: presence and size of ulcers, proportion of surface covered by ulcers, proportion of surface affected by disease, and presence and severity of stenosis. The total SES-CD is calculated as the sum of the 4 variables for the 5 bowel segments: (ileum; right, transverse, and left colon; and rectum): presence and size of ulcers (none = score 0; diameter 0.1-0.5 cm = score 1; 0.5-2 cm = score 2; greater than (\>) 2 cm = score 3); extent of ulcerated surface (none = 0; less than (\<) 10% = 1; 10-30% = 2; \>30% = 3); extent of affected surface (none = 0; \<50% = 1; 50-75% = 2; \>75% = 3); and presence and type of narrowings (none=0; single, can be passed=1; multiple, can be passed=2; cannot be passed=3). Total SES-CD scores range from 0 to 56, with higher scores indicating more severe disease.
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [2]
0
0
Percentage of Participants Achieving Patient Reported Outcome Remission at Week 12
Query!
Assessment method [2]
0
0
PRO remission is defined as stool frequency (SF) =2.5 and abdominal pain (AP) =1 and no worse than baseline at week 12. SF captures the number of liquid or very soft stools. AP score is classified as 0=none, 1=mild, 2=moderate, 3=severe.
Query!
Timepoint [2]
0
0
Week 12
Query!
Secondary outcome [3]
0
0
Mean Change From Baseline on the Patient Global Rating - Severity (PGRS) Crohn's Disease Score at Week 12
Query!
Assessment method [3]
0
0
The PGRS is a 1-item patient-rated questionnaire designed to assess the participant's rating of their disease symptom severity over the past 24 hours. Responses are graded on a 6-point scale in which a score of 1 indicates the subject has no symptoms (that is, "none") and a score of 6 indicates that the participant's symptom are "very severe." Least Squares Mean (LS Mean) was calculated using Mixed Model for Repeated Measures (MMRM) model with treatment, geographic region, geographic region, prior biologic CD therapy use (prior biologic experience versus prior biologic naive), baseline score, visit, and the interaction of treatment-by-visit and baseline-by-visit as fixed factors.
Query!
Timepoint [3]
0
0
Baseline, Week 12
Query!
Secondary outcome [4]
0
0
Mean of Patient Global Rating - Change (PGRC) Crohn's Disease Score at Week 12
Query!
Assessment method [4]
0
0
The PGRC scale is a patient-rated instrument designed to assess the participant's rating of change in their symptom(s). Responses are graded on a 7-point Likert scale in which a score of 1 indicates that the participant's symptom is "very much better," a score of 4 indicates that the participant's symptom has experienced "no change," and a score of 7 indicates that the participant's symptom is "very much worse."
Query!
Timepoint [4]
0
0
Baseline, Week 12
Query!
Secondary outcome [5]
0
0
Mean Change From Baseline on the Inflammatory Bowel Disease Questionnaire (IBDQ) Score at Week 12
Query!
Assessment method [5]
0
0
The IBDQ is a 32-item self-administered questionnaire. The IBDQ has 4 dimensions: bowel symptoms (10 items), systemic symptoms (5 items), emotional function (12 items), and social function (5 items). Responses are graded on a 7-point Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." Scores range from 32 to 224; a higher score indicates a better quality of life. LS Mean was calculated using Mixed Model for Repeated Measures (MMRM) model with treatment, geographic region, geographic region, prior biologic CD therapy use (prior biologic experience versus prior biologic naive), baseline score, visit, and the interaction of treatment-by-visit and baseline-by-visit as fixed factors.
Query!
Timepoint [5]
0
0
Baseline, Week 12
Query!
Secondary outcome [6]
0
0
Mean Change From Baseline on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 12
Query!
Assessment method [6]
0
0
The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale is a13-item, symptom-specific questionnaire that specifically assesses the participant's self-reported severity of fatigue and its impact upon daily activities and functioning. The FACIT-F uses a numeric rating scale of 0-4 associated with a range over "Not at all" to "Very much" for each item to assess fatigue and its impact in the past 7 days. Total scores range from 0 to 52, with higher scores indicating less fatigue. LS Mean was calculated using Mixed Model for Repeated Measures (MMRM) model with treatment, geographic region, geographic region, prior biologic CD therapy use (prior biologic experience versus prior biologic naive), baseline score, visit, and the interaction of treatment-by-visit and baseline-by-visit as fixed factors.
Query!
Timepoint [6]
0
0
Baseline, Week 12
Query!
Secondary outcome [7]
0
0
Mean Change From Baseline on the 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores at Week 12
Query!
Assessment method [7]
0
0
The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains:physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, 2 component scores (MCS and PCS). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing individual items and transforming scores into a 0 to 100 scale with higher scores indicating better health status or functioning. LS Mean was calculated using Mixed Model for Repeated Measures (MMRM) model with treatment, geographic region, geographic region, prior biologic CD therapy use (prior biologic experience versus prior biologic naive), baseline score, visit, and the interaction of treatment-by-visit and baseline-by-visit as fixed factors.
Query!
Timepoint [7]
0
0
Baseline, Week 12
Query!
Secondary outcome [8]
0
0
Population Pharmacokinetics (PopPK): Mean Population Clearance of Mirikizumab
Query!
Assessment method [8]
0
0
Population mean (between-subject coefficient variance \[CV %\]) apparent clearance. Clearance is estimated based on concentration data collected in the time frame of 0-208 weeks.
Query!
Timepoint [8]
0
0
Week 0, 4, 8: Predose, end of infusion; Week 2; 4; 6; 8, 11-12; 12-13; 16; 20; 24; 28; 36; 44; 52; 60; 68; 76; 84; 92; 104; 108; 112; 120; 128; 136; 144; 156; 164; 172; 180; 188; 196 and 208 weeks post infusion
Query!
Secondary outcome [9]
0
0
Population Pharmacokinetics (PopPK): Mean Population Volume of Distribution of Mirikizumab
Query!
Assessment method [9]
0
0
Population mean (between-subject coefficient variance \[CV %\]) apparent volume of distribution. Volume of distribution is estimated based on concentration data collected in the time frame of 0-208 weeks.
Query!
Timepoint [9]
0
0
Week 0, 4, 8: Predose, end of infusion; Week 2; 4; 6; 8, 11-12; 12-13; 16; 20; 24; 28; 36; 44; 52; 60; 68; 76; 84; 92; 104; 108; 112; 120; 128; 136; 144; 156; 164; 172; 180; 188; 196 and 208 weeks post infusion
Query!
Eligibility
Key inclusion criteria
* Active Crohn's Disease (CD) as determined by the SES-CD, and participant reported stool frequency and abdominal pain.
* Inadequate response or failure to tolerate at least one of the following: aminosalicylates; budesonide; systemic corticosteroids; immunosuppressants (eg, azathioprine, 6-mercaptopurine, or methotrexate); or prior exposure to biologics for the treatment of CD.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Have complications of CD such as strictures, stenoses, or any other manifestation for which surgery might be indicated, or that could confound the evaluation of efficacy.
* Diagnosis of conditions affecting the digestive tract, such as ulcerative colitis, indeterminate colitis, fistulizing disease, abdominal or perianal abscess, adenomatous colonic polyps not excised, colonic mucosal dysplasia, and short bowel syndrome.
* Have had any kind of bowel resection, diversion, or placement of a stoma within 6 months or any other intra-abdominal surgery within 3 months prior to screening.
* Are unsuitable for inclusion in the study in the opinion of the investigator or sponsor for any reason that may compromise the subject's safety or confound data interpretation.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
14/12/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
5/02/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
191
Query!
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment hospital [2]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [3]
0
0
Ballarat Health Services - Base Hospital - Ballarat
Query!
Recruitment hospital [4]
0
0
St Vincents Hospital Melbourne - Fitzroy
Query!
Recruitment postcode(s) [1]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [2]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [3]
0
0
3350 - Ballarat
Query!
Recruitment postcode(s) [4]
0
0
3065 - Fitzroy
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Indiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Kentucky
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Louisiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Maryland
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Michigan
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Minnesota
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Missouri
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Nevada
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New Jersey
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New York
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
North Carolina
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Ohio
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Oklahoma
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Rhode Island
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Tennessee
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Texas
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Utah
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Washington
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Brussel
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Gent
Query!
Country [28]
0
0
Canada
Query!
State/province [28]
0
0
Ontario
Query!
Country [29]
0
0
Czechia
Query!
State/province [29]
0
0
Czech Republic
Query!
Country [30]
0
0
Czechia
Query!
State/province [30]
0
0
Hradec Kralove
Query!
Country [31]
0
0
Czechia
Query!
State/province [31]
0
0
Olomouc
Query!
Country [32]
0
0
Czechia
Query!
State/province [32]
0
0
Praha 4 - Krc
Query!
Country [33]
0
0
Czechia
Query!
State/province [33]
0
0
Praha 5
Query!
Country [34]
0
0
Czechia
Query!
State/province [34]
0
0
Zlin
Query!
Country [35]
0
0
Hungary
Query!
State/province [35]
0
0
Budapest
Query!
Country [36]
0
0
Hungary
Query!
State/province [36]
0
0
Vac
Query!
Country [37]
0
0
Japan
Query!
State/province [37]
0
0
Chiba-Ken
Query!
Country [38]
0
0
Japan
Query!
State/province [38]
0
0
Fukoka
Query!
Country [39]
0
0
Japan
Query!
State/province [39]
0
0
Fukuoka-Ken
Query!
Country [40]
0
0
Japan
Query!
State/province [40]
0
0
Hokkaido
Query!
Country [41]
0
0
Japan
Query!
State/province [41]
0
0
Kagoshima
Query!
Country [42]
0
0
Japan
Query!
State/province [42]
0
0
Kanagawa
Query!
Country [43]
0
0
Japan
Query!
State/province [43]
0
0
Miyagi-Ken
Query!
Country [44]
0
0
Japan
Query!
State/province [44]
0
0
Osaka-Fu
Query!
Country [45]
0
0
Japan
Query!
State/province [45]
0
0
Tokyo
Query!
Country [46]
0
0
Japan
Query!
State/province [46]
0
0
Toyama
Query!
Country [47]
0
0
Japan
Query!
State/province [47]
0
0
Fukuoka
Query!
Country [48]
0
0
Netherlands
Query!
State/province [48]
0
0
Noord Brabant
Query!
Country [49]
0
0
Netherlands
Query!
State/province [49]
0
0
Amsterdam
Query!
Country [50]
0
0
Netherlands
Query!
State/province [50]
0
0
Nijmegen
Query!
Country [51]
0
0
Netherlands
Query!
State/province [51]
0
0
Rotterdam
Query!
Country [52]
0
0
Poland
Query!
State/province [52]
0
0
Bydgoszcz
Query!
Country [53]
0
0
Poland
Query!
State/province [53]
0
0
Lublin
Query!
Country [54]
0
0
Poland
Query!
State/province [54]
0
0
Poznan
Query!
Country [55]
0
0
Poland
Query!
State/province [55]
0
0
Rzeszow
Query!
Country [56]
0
0
Poland
Query!
State/province [56]
0
0
Szczecin
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Warszawa
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Wroclaw
Query!
Country [59]
0
0
Romania
Query!
State/province [59]
0
0
Bihor
Query!
Country [60]
0
0
Romania
Query!
State/province [60]
0
0
Bucuresti
Query!
Country [61]
0
0
Romania
Query!
State/province [61]
0
0
Timisoara
Query!
Country [62]
0
0
Russian Federation
Query!
State/province [62]
0
0
Novosibirsk
Query!
Country [63]
0
0
Russian Federation
Query!
State/province [63]
0
0
Omsk
Query!
Country [64]
0
0
Russian Federation
Query!
State/province [64]
0
0
Perm
Query!
Country [65]
0
0
Russian Federation
Query!
State/province [65]
0
0
Pushkin
Query!
Country [66]
0
0
Russian Federation
Query!
State/province [66]
0
0
Samara
Query!
Country [67]
0
0
Russian Federation
Query!
State/province [67]
0
0
St. Petersburg
Query!
Country [68]
0
0
Russian Federation
Query!
State/province [68]
0
0
Ulyanovsk
Query!
Country [69]
0
0
Switzerland
Query!
State/province [69]
0
0
Zürich
Query!
Country [70]
0
0
Ukraine
Query!
State/province [70]
0
0
Kyiv
Query!
Country [71]
0
0
Ukraine
Query!
State/province [71]
0
0
Lviv
Query!
Country [72]
0
0
Ukraine
Query!
State/province [72]
0
0
Odesa
Query!
Country [73]
0
0
Ukraine
Query!
State/province [73]
0
0
Uzhgorod
Query!
Country [74]
0
0
Ukraine
Query!
State/province [74]
0
0
Vinnytsia
Query!
Country [75]
0
0
Ukraine
Query!
State/province [75]
0
0
Vinnytsya
Query!
Country [76]
0
0
Ukraine
Query!
State/province [76]
0
0
Zaporizhzhia
Query!
Country [77]
0
0
United Kingdom
Query!
State/province [77]
0
0
Glasgow
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the safety and effectiveness of the study drug Mirikizumab in participants with active Crohn's Disease.
Query!
Trial website
https://clinicaltrials.gov/study/NCT02891226
Query!
Trial related presentations / publications
Sands BE, Peyrin-Biroulet L, Kierkus J, Higgins PDR, Fischer M, Jairath V, Hirai F, D'Haens G, Belin RM, Miller D, Gomez-Valderas E, Naegeli AN, Tuttle JL, Pollack PF, Sandborn WJ. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease. Gastroenterology. 2022 Feb;162(2):495-508. doi: 10.1053/j.gastro.2021.10.050. Epub 2021 Nov 5.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Query!
Available to whom?
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://vivli.org/
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/26/NCT02891226/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/26/NCT02891226/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT02891226